| Partnership for Research on Ebola VACcinations (NCT02876328) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-03-27 |
| A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers (NCT02891980) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-03-24 |
| Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME Study) (NCT02707042) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-03-22 |
| Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area (NCT03008122) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-03-21 |
| Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women (NCT02651259) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-03-13 |
| Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults (NCT02797171) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-03-01 |
| Etiology of Eczema Herpeticum (EH) (NCT03038932) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-02-22 |
| Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults (NCT03049488) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-02-22 |
| VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults (NCT03015181) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-02-21 |
| Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine (NCT03055000) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-02-15 |
| Impact of Malaria on Pregnant Women in Ouelessebougou, Mali (NCT02974608) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-02-15 |
| Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids (NCT02798523) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-01-24 |
| H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology (NCT03014310) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-01-09 |
| Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205 (NCT02852005) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-01-01 |
| Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients (NCT02741323) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-01-01 |
| Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men (NCT02720094) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-12-19 |
| VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults (NCT02996461) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-12-12 |
| Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases) (NCT02974595) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-12-09 |
| Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge (NCT02639299) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-12-08 |
| Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults (NCT02915016) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-12-07 |
| Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children (NCT02891915) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-12-02 |
| Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant (NCT02957656) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-12-01 |
| Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome (NCT02996448) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-11-17 |
| H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses (NCT02921997) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-11-07 |
| Auranofin for Giardia Protozoa (NCT02736968) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-11-06 |
| A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. (NCT02963909) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-11-01 |
| Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (NCT02968849) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-10-26 |
| Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali (NCT02942277) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-10-21 |
| Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae (NCT02961751) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-10-19 |
| ZIKA Vaccine in Naive Subjects (NCT02952833) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-10-14 |
| Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers (NCT01123499) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-10-06 |
| Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age (NCT02890381) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-10-05 |
| Treg Therapy in Subclinical Inflammation in Kidney Transplantation (NCT02711826) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-09-20 |
| PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States (NCT02773979) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-09-12 |
| Post-Traumatic Stress Symptoms (PTSS) in Transplant Recipients (NCT02892266) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-09-01 |
| Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age (NCT02948127) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-09-01 |
| Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease (NCT02883426) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-09-01 |
| PfSPZ Challenge in Non-immune Adults in Baltimore, USA (NCT02780154) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-25 |
| Type 1 Diabetes Extension Study (NCT02734277) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-18 |
| H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults (NCT02624219) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-16 |
| Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis (NCT02583048) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-15 |
| Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults (NCT02840487) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-02 |
| Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection (NCT02664415) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-01 |
| Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632 (NCT02779140) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-01 |
| Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age (NCT02952339) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-01 |
| Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30 (NCT02873260) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-01 |
| Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age (NCT02794870) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-07-15 |
| A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers (NCT02743455) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-07-05 |
| GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen (NCT02818582) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-07-01 |
| A Cohort Study of Operationally Tolerant Allograft Recipients (NCT02743793) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-06-30 |
| Safety and Immune Response to a Clade C DNA HIV Vaccine (NCT02997969) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-06-21 |
| Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction (NCT02474199) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-06-06 |
| LACTIN-V Study for Recurrent Bacterial Vaginosis (NCT02766023) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-06-03 |
| Phase 1 Study of dmLT ID Vaccination in Healthy Adults (NCT02531685) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-06-02 |
| Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption (NCT02788175) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-05-28 |
| Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults (NCT02788188) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-05-28 |
| Magnesium Supplementation in People With XMEN Syndrome (NCT02496676) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-05-17 |
| Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults (NCT02475655) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-05-16 |
| Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women (NCT02568215) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-05-01 |
| Cefixime / Azithromycin pK Study (NCT02708992) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-28 |
| Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (NCT02603146) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-27 |
| Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND) (NCT02519777) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-21 |
| Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis (NCT02709005) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-14 |
| Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso (NCT02663700) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-07 |
| Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis (NCT02734186) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-06 |
| Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men (NCT02716675) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-06 |
| Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection (NCT02591420) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-04-01 |
| Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh (NCT02678455) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-03-01 |
| Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults (NCT02654080) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-03-01 |
| Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age (NCT02879266) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-02-01 |
| Cockroach Nasal Allergen Challenge Pilot (NCT02710136) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-02-01 |
| Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance (NCT02534727) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-01-27 |
| Impact of Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Doneguebougou, Mali (NCT02659566) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-01-15 |
| H7N9 Boost in Healthy Adults (NCT02586792) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-01-12 |
| CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE) (NCT02652546) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-01-09 |
| Artemether-lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in Mali (NCT02645604) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-01-01 |
| Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever) (NCT02663674) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-12-29 |
| Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination (NCT02485639) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-12-23 |
| CLAD Phenotype Specific Risk Factors and Mechanisms (NCT02631720) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-12-22 |
| High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease (NCT02629120) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-12-17 |
| Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation (NCT02533180) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-12-15 |
| Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali (NCT02627456) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-12-09 |
| Cardiometabolic Effects of Eplerenone in HIV Infection (NCT02629094) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-12-02 |
| Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia (NCT02612545) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-11-20 |
| Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults (NCT02562482) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-11-18 |
| Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults (NCT02599896) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-11-16 |
| Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers (NCT02454699) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-11-10 |
| Effects of Inhibiting Early Inflammation in Kidney Transplant Patients (NCT02495077) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-11-02 |
| Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A (NCT02572817) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-11-01 |
| Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers (NCT02594189) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-10-31 |
| Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies (NCT02473224) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-10-28 |
| Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects (NCT02508376) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-10-22 |
| Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency (NCT02199496) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-10-19 |
| Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy (NCT02502890) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-10-01 |
| Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children (NCT02601612) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-10-01 |
| Subcutaneous Immunotherapy for Mouse in Adults (NCT02532179) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-10-01 |
| Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy (NCT02194998) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-09-16 |
| Emtricitabine/Tenofovir Alafenamide as Salvage ART (NCT02556333) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-09-16 |
| Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults (NCT02544048) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-09-04 |
| Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1) (NCT02337842) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-09-01 |